Skip to content

Neurofeedback and Nomophobia in Young Adults

Effectiveness of a Neurofeedback Intervention on Symptoms of Anxiety and Psychological Distress Associated With Smartphone Use in Young Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06188910
Enrollment
40
Registered
2024-01-03
Start date
2024-04-01
Completion date
2025-02-28
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Biofeedback

Brief summary

Introduction: Given the growing increase in addiction to social networks and smartphone use in young people and its implications for health, it is necessary to investigate effective interventions for the appropriate use of these technologies and coping with possible signs of addiction. Objective: To evaluate the effect of an intervention based on neurofeedback techniques on anxiety and other disorders associated with problematic use of mobile phones and the internet in young adults. Methodology: Randomised controlled clinical trial with two parallel groups: an intervention group (IG) and a control group (CG). The study population will be young adults aged 18-30 years. A sample size of 40 participants has been estimated, 20 in each group to detect a difference of 3.9 points or more on the DASS-21 anxiety questionnaire. All participants will receive an educational workshop on the responsible use of new technologies and the promotion of healthy lifestyles. The IG, in addition to this educational workshop, will receive 25 neurofeedback sessions during 12 weeks, 2-3 sessions/week with the MUSE neurofeedback device. A baseline and 3-month post-intervention assessment will be conducted for both groups to study change variables related to smartphone addiction (Smartphone Addiction Scale-Short Version (SAS-SV)), nomophobia (Nomophobia Questionnaire (NMP-Q)), depression, anxiety and stress (Depression, Anxiety and Stress Scale 21-item (DASS-21)) and sleep quality.

Interventions

OTHERNeurofeedback

Conducting neurofeedback sessions guided by a researcher

OTHERHealth education

Health education on mobile phone addiction

Sponsors

Instituto de Investigación Biomédica de Salamanca
CollaboratorOTHER
Gerencia Regional de Salud de Castilla y Leon
CollaboratorOTHER
University of Salamanca
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Have one or more mobile devices such as smartphones. * Have a compatible mobile device to install and use the Muse: EEG Meditation & Sleep application. * Be fully functional. * Willingness to voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

* History of severe psychiatric disorders (such as schizoaffective disorders, bipolar disorder, major depressive episode with symptoms or other non-organic psychotic disorders) requiring psychiatric treatment in the 6 months prior to study entry. * History of brain injury or other problems contraindicating the use of neurofeedback.

Design outcomes

Primary

MeasureTime frameDescription
AnxietyBaseline, 3-monthsAnxiety evaluated through Depression, Anxiety and Stress Scale 21-item (DASS-21). Minimum 0 - maximum 63

Secondary

MeasureTime frameDescription
NomophobiaBaseline, 3-monthsNomophobia evaluated through Nomophobia Questionnaire (NMP-Q). Minimum 20 - maximum 140
Sleep QualityBaseline, 3-monthsSleep quality evaluated through Atenas questionnaire. Minimum 0 - maximum 24

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026